Specimen Collection Cards

Global Specimen Collection Cards Market to Reach US$559.7 Million by 2030

The global market for Specimen Collection Cards estimated at US$450.8 Million in the year 2024, is expected to reach US$559.7 Million by 2030, growing at a CAGR of 3.7% over the analysis period 2024-2030. Blood, one of the segments analyzed in the report, is expected to record a 3.7% CAGR and reach US$221.1 Million by the end of the analysis period. Growth in the Saliva segment is estimated at 2.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$122.8 Million While China is Forecast to Grow at 6.8% CAGR

The Specimen Collection Cards market in the U.S. is estimated at US$122.8 Million in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$112.3 Million by the year 2030 trailing a CAGR of 6.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.5% and 2.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.1% CAGR.

Global Specimen Collection Cards Market – Key Trends & Drivers Summarized

Why Are Specimen Collection Cards Gaining Critical Importance in Modern Diagnostics?

Specimen collection cards have become an essential tool in modern medical diagnostics, public health surveillance, and biomedical research, primarily due to their ability to simplify biological sample collection, preservation, and transportation. Designed to collect and store dried blood spots (DBS), saliva, buccal cells, or other biological fluids on treated paper or membranes, these cards offer a minimally invasive, low-cost, and logistically efficient solution for sample acquisition—especially in remote or resource-limited settings. With global healthcare systems increasingly focused on decentralization and preventive care, the use of specimen collection cards is expanding across applications such as newborn screening, infectious disease monitoring, genetic testing, forensic analysis, and even personalized medicine. Their stability at ambient temperatures eliminates the need for cold-chain logistics, reducing both complexity and cost. Moreover, the pandemic-era emphasis on mail-in testing and at-home sample collection has brought specimen collection cards into the spotlight as part of scalable diagnostics and bio-surveillance strategies. Whether in clinical trials, field-based epidemiology, or telehealth settings, these cards are supporting the global shift toward more accessible and resilient health monitoring frameworks.

How Are Innovations in Card Design and Sample Stability Enhancing Market Adoption?

Technological advancements in filter paper treatment, analyte stabilization, and multi-sample integration are transforming the capabilities of specimen collection cards. Manufacturers are now producing cards with enhanced chemical coatings that preserve nucleic acids (DNA, RNA) and proteins more effectively, extending shelf life and improving the integrity of analytes under varied environmental conditions. Some cards are embedded with indicator dyes for volume verification, ensuring sufficient and consistent sample collection by users in home-testing or field environments. Other innovations include multi-zone collection areas for different sample types, integrated barcoding for traceability, and tamper-evident packaging that meets regulatory compliance for forensic and clinical use. Dried blood spot cards, the most widely used format, are increasingly optimized for downstream applications such as PCR, mass spectrometry, ELISA, and next-generation sequencing (NGS), thereby aligning with high-sensitivity diagnostic workflows. Automation-compatible formats are also being developed to streamline laboratory processing. These product-level improvements are making specimen collection cards more versatile, user-friendly, and compatible with global diagnostic supply chains—key factors in enabling broader adoption in both high-throughput laboratories and point-of-care environments.

Where Is Demand Rising Fastest, and Which Use Cases Are Leading Growth?

Demand for specimen collection cards is rising rapidly across clinical, research, and public health sectors, with particularly strong growth in applications such as newborn screening, infectious disease diagnostics, and genetic testing. Newborn screening programs remain the largest and most established user of dried blood spot cards, especially in North America, Europe, and parts of Asia-Pacific, where testing for metabolic and genetic disorders is routine. The global expansion of early detection programs for HIV, hepatitis, and tuberculosis is also driving card usage in developing countries, where conventional phlebotomy and refrigerated sample transport may be limited. Direct-to-consumer (DTC) genetic testing companies are increasingly incorporating at-home collection cards into their kits, allowing customers to submit saliva or cheek swab samples for ancestry, carrier screening, or wellness reports. Biobanks and longitudinal cohort studies are using specimen cards to collect, store, and archive samples from large populations in a compact, cost-effective manner. Emerging areas like pharmacogenomics, forensic toxicology, and therapeutic drug monitoring are also adopting these tools for non-invasive, scalable sampling. Governments, NGOs, and academic researchers are collectively contributing to demand, particularly in the wake of global health crises where mass sampling and surveillance are needed quickly and efficiently.

What’s Driving the Long-term Growth of the Specimen Collection Cards Market?

The growth in the specimen collection cards market is driven by several interlinked factors tied to global health priorities, diagnostic decentralization, technological innovation, and regulatory evolution. A primary driver is the rising need for scalable, cost-effective sample collection tools that support early diagnosis, outbreak tracking, and personalized treatment—especially in low-resource or geographically dispersed populations. The shift toward home-based healthcare, remote patient monitoring, and digital diagnostics is further expanding the relevance of specimen cards as foundational tools for sample acquisition outside traditional healthcare settings. Increased investment in genetic testing, clinical research, and bio-banking is creating long-term demand for cards that can store samples with high analyte integrity and compatibility with downstream molecular workflows. In parallel, public health agencies are integrating specimen cards into epidemiological studies and vaccination monitoring, reinforcing their role in population health management. Regulatory recognition of dried blood spot and alternative specimen cards as valid sources for clinical-grade data is also helping to normalize their use in diagnostics. As global focus intensifies on health equity, disease prevention, and rapid response capabilities, specimen collection cards are set to remain a vital enabler—bridging the gap between patients and laboratories, wherever they are in the world.

SCOPE OF STUDY:

The report analyzes the Specimen Collection Cards market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Specimen (Blood, Saliva, Urine, Buccal Cells, Others); Material (Cotton & Cellulose-based, Fiber-based, Others); Application (New Born Screening, Infectious Diseases Testing, Therapeutic Drug Monitoring, Forensics, Research, Wellbeing / Health Monitoring, Other Applications)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 41 Featured) -

• Ahlstrom-Munksjö
• ARCHIMEDlife
• Becton, Dickinson and Company (BD)
• Capitainer AB
• Cardinal Health
• CENTOGENE N.V.
• DBS System SA
• Eastern Business Forms, Inc. (EBF)
• EUROIMMUN AG
• F. Hoffmann-La Roche Ltd
• GenTegra LLC
• Greiner Bio-One International GmbH
• Hemaxis
• Lipomic Healthcare
• Medline Industries, LP
• Mitra Microsampling Devices (Neoteryx)
• Munktell Filter AB
• Neoteryx LLC
• PerkinElmer, Inc.
• Phenomenex, Inc.
• QIAGEN N.V.
• RDA Spot
• SARSTEDT AG & Co. KG
• Shimadzu Scientific Instruments
• Sirchie Acquisition Company, LLC
• Synergy Medical Systems LLP
• Thomas Scientific
• VWR International, LLC
• Whatman (part of Cytiva)

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.